Stockscreener 앱 받기
13.08
1.79%
0.23
시간 외 거래:
12.52
-0.56
-4.28%
전일 마감가:
$12.85
열려 있는:
$12.85
하루 거래량:
4.94M
Relative Volume:
3.05
시가총액:
$1.12B
수익:
$139.71M
순이익/손실:
$-209.36M
주가수익비율:
-5.0698
EPS:
-2.58
순현금흐름:
$-160.60M
1주 성능:
-6.10%
1개월 성능:
-17.99%
6개월 성능:
-32.12%
1년 성능:
-33.60%
1일 변동 폭
$12.75
$13.15
1주일 범위
$12.75
$14.18
52주 변동 폭
$12.75
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
35 GATEHOUSE DRIVE, WALTHAM, MA
SNDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.08 | 1.12B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - The Eastern Progress Online
Franklin Resources Inc. Grows Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $13.26 amid market challenges - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowShould You Sell? - MarketBeat
State Street Corp Has $72.59 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
(SNDX) Technical Pivots with Risk Controls - Stock Traders Daily
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial - Marketscreener.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Time to Sell? - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.65 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
BNP Paribas Financial Markets Buys 16,663 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap DownTime to Sell? - MarketBeat
The Manufacturers Life Insurance Company Has $918,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Y Intercept Hong Kong Ltd Buys 61,916 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $14.99 amid market shifts By Investing.com - Investing.com South Africa
SNDX stock touches 52-week low at $14.99 amid market shifts - Investing.com Canada
SNDXSyndax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright - MarketBeat
While Syndax Pharmaceuticals (NASDAQ:SNDX) shareholders have made 85% in 5 years, increasing losses might now be front of mind as stock sheds 6.8% this week - Simply Wall St
Wellington Management Group LLP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Two Sigma Advisers LP Purchases 48,100 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Announces Additional Positive Data for Revuforj®? from Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial - Marketscreener.com
Syndax's Revuforj Shows Breakthrough 100% Response Rate in AML Clinical Trial Data - StockTitan
Charles Schwab Investment Management Inc. Grows Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Quantbot Technologies LP Acquires Shares of 2,542 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax's Revuforj Shows Remarkable 82% Response Rate in Leukemia Clinical Trials at ASH Meeting - StockTitan
Verition Fund Management LLC Has $1.53 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
BlackRock, Inc. Acquires Additional Shares in Syndax Pharmaceuti - GuruFocus.com
(SNDX) Proactive Strategies - Stock Traders Daily
Syndax Pharmaceuticals (STU:1T3) Change In Prepaid Assets : €-6.79 Mil (TTM As of Sep. 2024) - GuruFocus.com
Syndax Pharmaceuticals (STU:1T3) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
Point72 Asset Management L.P. Sells 67,086 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX (Syndax Pharmaceuticals) FCF Margin % : -498.58% (As of Sep. 2024) - GuruFocus.com
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Parkman Healthcare Partners LLC Has $9.78 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Awards Key Talent with Strategic Stock Options Package - StockTitan
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $37.64 Average PT from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Eventide Asset Management LLC Buys New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. announced that it expects to receive funding from Kyowa Hakko Kirin Co., Ltd. - Marketscreener.com
Syndax Pharmaceuticals, Inc. announced that it expects to receive $30 million in funding from Hercules Capital, Inc. - Marketscreener.com
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference - StockTitan
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Propel Bio Management LLC - MarketBeat
Syndax Pharmaceuticals' SWOT analysis: stock outlook brightens on FDA approvals - Investing.com Canada
Long Term Trading Analysis for (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co. - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Lowered by StockNews.com - Defense World
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):